Bolt Biotherapeutics Stock Analysis
BOLT Stock | USD 0.60 0.02 3.45% |
Bolt Biotherapeutics is undervalued with Real Value of 1.68 and Target Price of 5.0. The main objective of Bolt Biotherapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Bolt Biotherapeutics is worth, separate from its market price. There are two main types of Bolt Biotherapeutics' stock analysis: fundamental analysis and technical analysis.
The Bolt Biotherapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Bolt Biotherapeutics is usually not traded on Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday. Bolt Stock trading window is adjusted to America/New York timezone.
Bolt |
Bolt Stock Analysis Notes
About 58.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.32. Some equities with similar Price to Book (P/B) outperform the market in the long run. Bolt Biotherapeutics recorded a loss per share of 1.71. The entity last dividend was issued on the August 29, 2014. The firm had 3:2 split on the January 31, 2008. Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California. Bolt Biotherapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 91 people. For more info on Bolt Biotherapeutics please contact Randall Schatzman at 650 665 9295 or go to https://www.boltbio.com.Bolt Biotherapeutics Investment Alerts
Bolt Biotherapeutics generated a negative expected return over the last 90 days | |
Bolt Biotherapeutics has some characteristics of a very speculative penny stock | |
Bolt Biotherapeutics has high likelihood to experience some financial distress in the next 2 years | |
The company reported the previous year's revenue of 7.88 M. Net Loss for the year was (69.2 M) with profit before overhead, payroll, taxes, and interest of 1.62 M. | |
Bolt Biotherapeutics currently holds about 176.34 M in cash with (69.53 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.68, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
Bolt Biotherapeutics has a frail financial position based on the latest SEC disclosures | |
Roughly 58.0% of the company shares are held by institutions such as insurance companies | |
Latest headline from MacroaxisInsider: Disposition of 44000 shares by Sarah Nemec of Bolt Biotherapeutics at 3.08 subject to Rule 16b-3 |
Bolt Biotherapeutics Upcoming and Recent Events
3rd of April 2024 Upcoming Quarterly Report | View | |
9th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
3rd of April 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Bolt Largest EPS Surprises
Earnings surprises can significantly impact Bolt Biotherapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2023-05-11 | 2023-03-31 | -0.51 | -0.45 | 0.06 | 11 | ||
2023-11-09 | 2023-09-30 | -0.5 | -0.43 | 0.07 | 14 | ||
2023-03-29 | 2022-12-31 | -0.6 | -0.53 | 0.07 | 11 |
Bolt Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Blackrock Inc | 2024-06-30 | 267.1 K | Adar1 Capital Management Llc | 2024-09-30 | 245 K | Fmr Inc | 2024-09-30 | 115.4 K | Marquette Asset Management Inc. | 2024-06-30 | 113.8 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 67.4 K | Bridgeway Capital Management, Llc | 2024-09-30 | 60.2 K | Prudential Financial Inc | 2024-09-30 | 59.2 K | Two Sigma Securities, Llc | 2024-06-30 | 53.9 K | Ubs Group Ag | 2024-06-30 | 48.8 K | Tang Capital Management Llc | 2024-09-30 | 3.8 M | Vivo Capital, Llc | 2024-09-30 | 3.5 M |
Bolt Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 22.96 M.Bolt Profitablity
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.43) | (0.45) | |
Return On Capital Employed | (0.55) | (0.57) | |
Return On Assets | (0.43) | (0.45) | |
Return On Equity | (0.61) | (0.58) |
Management Efficiency
Bolt Biotherapeutics has return on total asset (ROA) of (0.2941) % which means that it has lost $0.2941 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5804) %, meaning that it created substantial loss on money invested by shareholders. Bolt Biotherapeutics' management efficiency ratios could be used to measure how well Bolt Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.45 in 2024. Return On Capital Employed is likely to drop to -0.57 in 2024. Non Current Liabilities Total is likely to gain to about 46.8 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 16.1 M in 2024.Last Reported | Projected for Next Year | ||
Book Value Per Share | 2.98 | 3.13 | |
Tangible Book Value Per Share | 2.98 | 3.13 | |
Enterprise Value Over EBITDA | (0.70) | (0.73) | |
Price Book Value Ratio | 0.38 | 0.39 | |
Enterprise Value Multiple | (0.70) | (0.73) | |
Price Fair Value | 0.38 | 0.39 | |
Enterprise Value | 51.8 M | 49.2 M |
The decision-making processes within Bolt Biotherapeutics are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Operating Margin (14.93) | Beta 0.916 | Return On Assets (0.29) | Return On Equity (0.58) |
Technical Drivers
As of the 26th of November, Bolt Biotherapeutics shows the Mean Deviation of 1.73, risk adjusted performance of (0.05), and Standard Deviation of 2.47. Bolt Biotherapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Bolt Biotherapeutics Price Movement Analysis
java.lang.NullPointerException: Cannot invoke "java.lang.Number.intValue()" because the return value of "sun.invoke.util.ValueConversions.primitiveConversion(sun.invoke.util.Wrapper, Object, boolean)" is null. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Bolt Biotherapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Bolt Biotherapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Bolt Biotherapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bolt Biotherapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bolt Biotherapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Bolt Biotherapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Bolt Biotherapeutics Outstanding Bonds
Bolt Biotherapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Bolt Biotherapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Bolt bonds can be classified according to their maturity, which is the date when Bolt Biotherapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Boeing Co 2196 Corp BondUS097023DG73 | View | |
US09778PAC95 Corp BondUS09778PAC95 | View | |
US09778PAA30 Corp BondUS09778PAA30 | View | |
US09778PAB13 Corp BondUS09778PAB13 | View | |
HSBC Holdings PLC Corp BondUS404280DR76 | View | |
US097793AE35 Corp BondUS097793AE35 | View | |
US097751BX80 Corp BondUS097751BX80 | View | |
BBDBCN 75 01 FEB 29 Corp BondUS097751BZ39 | View |
Bolt Biotherapeutics Predictive Daily Indicators
Bolt Biotherapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Bolt Biotherapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Bolt Biotherapeutics Forecast Models
Bolt Biotherapeutics' time-series forecasting models are one of many Bolt Biotherapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Bolt Biotherapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Bolt Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Bolt Biotherapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Bolt shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Bolt Biotherapeutics. By using and applying Bolt Stock analysis, traders can create a robust methodology for identifying Bolt entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | (8.79) | (9.23) | |
Operating Profit Margin | (9.67) | (10.16) | |
Net Loss | (8.79) | (9.23) | |
Gross Profit Margin | 0.76 | 0.80 |
Current Bolt Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Bolt analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Bolt analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
5.0 | Hold | 4 | Odds |
Most Bolt analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Bolt stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Bolt Biotherapeutics, talking to its executives and customers, or listening to Bolt conference calls.
Bolt Stock Analysis Indicators
Bolt Biotherapeutics stock analysis indicators help investors evaluate how Bolt Biotherapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Bolt Biotherapeutics shares will generate the highest return on investment. By understating and applying Bolt Biotherapeutics stock analysis, traders can identify Bolt Biotherapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow | 10.8 M | |
Common Stock Shares Outstanding | 37.8 M | |
Total Stockholder Equity | 112.7 M | |
Property Plant And Equipment Net | 24.1 M | |
Cash And Short Term Investments | 102.2 M | |
Cash | 10.8 M | |
Accounts Payable | 3 M | |
Net Debt | 9.4 M | |
50 Day M A | 0.6308 | |
Total Current Liabilities | 20.5 M | |
Other Operating Expenses | 84.1 M | |
Non Current Assets Total | 54.1 M | |
Non Currrent Assets Other | 3.6 M | |
Stock Based Compensation | 9.2 M |
Additional Tools for Bolt Stock Analysis
When running Bolt Biotherapeutics' price analysis, check to measure Bolt Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bolt Biotherapeutics is operating at the current time. Most of Bolt Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Bolt Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bolt Biotherapeutics' price. Additionally, you may evaluate how the addition of Bolt Biotherapeutics to your portfolios can decrease your overall portfolio volatility.